The present work focused on evaluating the feasibility of fused deposition modeling (FDM) in the development of a dosage form containing Timapiprant (TMP), also known as CHF6532, which is a novel active molecule indicated in the potential treatment of eosinophilic asthma upon oral administration. The resulting product could be an alternative, with potential towards personalization, of immediate release (IR) tablets used in the clinical studies. Formulations based on different polymeric carriers were screened, leading to the identification of a polyvinyl alcohol-based one, which turned out acceptable for versatility in terms of active ingredient content, printability and dissolution performance (i.e. capability to meet the dissolution specification set, envisaging >80% of the drug dissolved within 30 min). Following an in-depth evaluation on the influence of TMP solid state and of the voids volume resulting from printing on dissolution, few prototypes with shapes especially devised for therapy customization were successfully printed and were compliant with the dissolution specification set.

Investigation on the use of fused deposition modeling for the production of IR dosage forms containing Timapiprant / M. Uboldi, A. Chiappa, M. Pertile, A. Piazza, S. Tagliabue, A. Foppoli, L. Palugan, A. Gazzaniga, L. Zema, A. Melocchi. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. X. - ISSN 2590-1567. - 5:(2023), pp. 100152.1-100152.14. [10.1016/j.ijpx.2022.100152]

Investigation on the use of fused deposition modeling for the production of IR dosage forms containing Timapiprant

M. Uboldi
Primo
;
A. Foppoli;L. Palugan
;
A. Gazzaniga;L. Zema
Penultimo
;
A. Melocchi
Ultimo
2023

Abstract

The present work focused on evaluating the feasibility of fused deposition modeling (FDM) in the development of a dosage form containing Timapiprant (TMP), also known as CHF6532, which is a novel active molecule indicated in the potential treatment of eosinophilic asthma upon oral administration. The resulting product could be an alternative, with potential towards personalization, of immediate release (IR) tablets used in the clinical studies. Formulations based on different polymeric carriers were screened, leading to the identification of a polyvinyl alcohol-based one, which turned out acceptable for versatility in terms of active ingredient content, printability and dissolution performance (i.e. capability to meet the dissolution specification set, envisaging >80% of the drug dissolved within 30 min). Following an in-depth evaluation on the influence of TMP solid state and of the voids volume resulting from printing on dissolution, few prototypes with shapes especially devised for therapy customization were successfully printed and were compliant with the dissolution specification set.
3D printing; Immediate release; Oral administration; BCS class II drug; Personalized therapy; Dissolution; Pycnometric analysis
Settore CHIM/09 - Farmaceutico Tecnologico Applicativo
24-dic-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2590156722000433-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 8.39 MB
Formato Adobe PDF
8.39 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/950311
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact